About Megan Heaps
Articles by Megan Heaps
EHA 2024: How Effective is Elritercept for Low-Risk MDS Patients?Aug 05, 2024
How Can Patient Navigators Help Me Access Cancer Care?Aug 01, 2024
ASCO 2024: How Effective is Liso-cel for Richter Transformation?Jul 31, 2024
EHA 2024: 4 Years on, Ibrutinib + Venetoclax Keeps High-Risk CLL in RemissionJul 22, 2024
“Off-the-Shelf" CAR T-Cell Therapy for CLLJul 17, 2024
Making Kidney Disease a Global Health PriorityJul 17, 2024
Relapsed/Refractory CLL Treatment OptionsJul 16, 2024
EHA 2024: Patient Outcomes from Oral Azacitidine Maintenance TherapyJul 16, 2024
EHA 2024: Can Patients Over 75 Be Treated with CAR T-cell Therapy?Jul 16, 2024
Epcoritamab (Epkinly) Now FDA-Approved for Relapsed/Refractory Follicular LymphomaJul 15, 2024
Discover MyeloMATCH: A New Approach to Accelerate AML and MDS ResearchJul 12, 2024
Discover MyeloMATCH: A New Approach to Accelerate AML and MDS ResearchJul 12, 2024
ASCO 2024: Reducing Ibrutinib Dose Impacts Time to Next CLL TreatmentJul 09, 2024
High Copper and Low Zinc Consumption Disrupt p53 FunctionJul 08, 2024
Understanding Your CLL Treatment Options: Fixed-Duration vs. Continuous-Duration TherapiesJul 03, 2024
ASCO 2024: How Can Palliative Care Help AML Patients?Jul 02, 2024
ASCO 2024: How Can Palliative Care Help High-Risk MDS Patients?Jul 02, 2024
What is the Relationship Between Vitamin D and Myelofibrosis?Jun 28, 2024
Mindfulness Technique for Myeloma Patients: Wise MindJun 27, 2024
ASCO 2024: How Effective is Prexigebersen for AML?Jun 26, 2024
What is Relapsed & Refractory AML?Jun 23, 2024
First R/R Myeloma Patient Treated with New BCMA-Directed Bispecific Antibody in Phase 3 StudyJun 21, 2024
What is Remission in AML?Jun 20, 2024
ASCO 2024: Does Gemtuzumab Before SCT Increase Liver-Related Side Effects for AML Patients?Jun 19, 2024